immune effector cell-associated neurotoxicity syndrome (ICANS)

From Aaushi
Jump to navigation Jump to search

Etiology

Pathology

neurotoxicity

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Management

More general terms

References

  1. Siegler EL, Kenderian SS Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol. 2020. Aug 28;11:1973 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32983132 PMCID: PMC7485001 Free PMC article https://www.frontiersin.org/articles/10.3389/fimmu.2020.01973/full
  2. Holtzman NG, Xie H, Bentzen S et al Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol. 2021 Jan 30;23(1):112-121 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32750704 PMCID: PMC7850044 Free PMC article
  3. 3.0 3.1 3.2 3.3 3.4 Mohn N, Bonda V, Grote-Levi L et al Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract. 2022 Jan 10;4(1):1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35000613 PMCID: PMC8744256 Free PMC article
  4. 4.0 4.1 4.2 4.3 4.4 Holzman NG et al Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes. Blood. 2019. 134(Suppl 1)3239 https://ashpublications.org/blood/article/134/Supplement_1/3239/423803/Immune-Effector-Cell-Associated-Neurotoxicity